You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Details for Patent: 11,000,567


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,000,567
Title:Glycopeptide compositions
Abstract:Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Inventor(s):Ivona Jasprica, Sabina Keser, Katarina Pindric
Assignee: Hikma Pharmaceuticals USA Inc
Application Number:US16/677,057
Patent Claim Types:
see list of patent claims
Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,000,000: A Detailed Analysis

Introduction

On May 11, 2021, the United States Patent and Trademark Office (USPTO) issued U.S. patent number 11,000,000, a milestone that highlights the enduring tradition of American innovation. This patent, granted to co-inventors Saravana B. Kumar and Jason S. Diedering of 4C Medical Technologies, Inc., is a significant marker in the history of U.S. patents. Here, we delve into the details of this patent, its scope, claims, and the broader patent landscape.

Background on U.S. Patent Number 11,000,000

The patent in question is for a utility patent titled "Repositioning Wires and Methods for Repositioning Prosthetic Heart Valve Devices Within a Heart Chamber and Related Systems, Devices, and Methods"[1][4].

Inventors and Their Journey

Saravana B. Kumar and Jason S. Diedering, the inventors behind this patent, exemplify the spirit of American entrepreneurship. Their journey began in a garage, where they worked tirelessly to develop a solution for treating severe mitral regurgitation. This invention is part of an ongoing U.S. clinical trial, demonstrating its potential to save lives[1].

Scope of the Patent

The scope of a patent is defined by its claims, which are the legal definitions of the inventor's protectable invention.

Claims Analysis

The claims in patent 11,000,000 are specific to the method and system for delivering, positioning, and repositioning a collapsible and expandable stent frame within a patient’s heart chamber. Here are some key aspects:

  • Independent Claims: These claims define the core invention and are crucial for determining the patent's scope. In this case, the independent claims focus on the novel method and system for heart valve device repositioning[1].
  • Dependent Claims: These claims build upon the independent claims, providing additional details and variations of the invention. They help in broadening the protection while ensuring the invention's core remains intact[5].

Patent Claims and Scope Metrics

Research on patent claims and scope provides valuable insights into the quality and breadth of patents.

Independent Claim Length and Count

Studies have shown that metrics such as independent claim length and count can be used to measure patent scope. Narrower claims, often indicated by shorter independent claim lengths and fewer claims, are associated with a higher probability of grant and a shorter examination process[3].

Application to Patent 11,000,000

While specific metrics for patent 11,000,000 are not publicly available, the fact that it was granted suggests that the claims were well-defined and met the USPTO's standards for clarity and novelty.

The Patenting Process

Understanding the patenting process is essential for grasping the significance and challenges associated with obtaining a patent like 11,000,000.

Timeline

The average U.S. utility patent application is pending for about three years, though this can vary significantly depending on the technology field. For instance, biotech and computer fields often experience longer waiting periods[5].

Patent Prosecution

The process of obtaining a patent involves multiple stages, including initial filing, office actions, and potential amendments. The USPTO may reject an application due to formalities or prior art issues, requiring the patent attorney to file written responses and amendments[5].

Economic and Innovation Impact

Patents like 11,000,000 contribute significantly to the economy and innovation landscape.

Economic Contribution

Patents are a driving force behind economic growth, encouraging innovation and investment. The issuance of patent 11,000,000 is a testament to the strength of the U.S. patent system, which has facilitated the granting of over 11 million patents since its inception[1][4].

Innovation During Crisis

The USPTO's response to the COVID-19 pandemic, including adjustments to facilitate remote work and special procedures for virus-related inventions, highlights the system's adaptability and commitment to innovation[4].

Historical Context of U.S. Patents

The U.S. patent system has a rich history that underscores its importance.

Early Patents

The first numbered patent, Patent No. 1, was issued in 1836 for a traction wheel for steam locomotives. This marked the beginning of a systematic approach to patent numbering, replacing the earlier "X-patents" that were identifiable only by the patentee's name and date of issue[1][4].

Milestones

The journey from Patent No. 1 to 11,000,000 has been marked by significant milestones, including the issuance of Patent No. 6,000,000 in 1999. The rapid increase in patent issuances over the past two decades reflects the accelerating pace of innovation[1][4].

Conclusion

The issuance of U.S. patent number 11,000,000 is a landmark event that celebrates American innovation and ingenuity. The patent, granted to Saravana B. Kumar and Jason S. Diedering, represents a significant advancement in medical technology and underscores the importance of the U.S. patent system in fostering innovation.

Key Takeaways

  • Innovation Milestone: Patent 11,000,000 marks a significant milestone in the history of U.S. patents.
  • Medical Breakthrough: The patent is for a method and system for repositioning prosthetic heart valve devices, a potential lifesaver.
  • Economic Impact: Patents contribute to economic growth and innovation.
  • Historical Context: The U.S. patent system has evolved significantly since its inception in 1836.
  • Patent Scope and Claims: The scope of a patent is defined by its claims, with metrics like independent claim length and count providing insights into patent quality.

FAQs

Q: What is the significance of U.S. patent number 11,000,000?

A: U.S. patent number 11,000,000 is a milestone that highlights the enduring tradition of American innovation and the strength of the U.S. patent system.

Q: Who are the inventors behind patent 11,000,000?

A: The inventors are Saravana B. Kumar and Jason S. Diedering of 4C Medical Technologies, Inc.

Q: What is the subject matter of patent 11,000,000?

A: The patent is for a method and system for delivering, positioning, and repositioning a collapsible and expandable stent frame within a patient’s heart chamber.

Q: How long does the patenting process typically take?

A: The average U.S. utility patent application is pending for about three years, though this can vary depending on the technology field.

Q: What are the economic benefits of patents like 11,000,000?

A: Patents encourage innovation, investment, and economic growth, contributing significantly to the national economy.

Sources

  1. United States Issues Patent Number 11,000,000 - Kim and Lahey
  2. Patent Claims Research Dataset - USPTO
  3. Patent Claims and Patent Scope - SSRN
  4. USPTO Issues Patent Number 11,000,000 - Maier & Maier
  5. Legal Protections - Office of Technology Transfer, Penn State

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,000,567

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hikma VANCOMYCIN vancomycin SOLUTION;INTRAVENOUS, ORAL 213895-001 Aug 26, 2021 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,000,567

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015341763 ⤷  Try for Free
Brazil 112017009405 ⤷  Try for Free
Canada 2964524 ⤷  Try for Free
Chile 2017001139 ⤷  Try for Free
China 107073072 ⤷  Try for Free
Colombia 2017005391 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.